小细胞肺癌免疫治疗的新进展

The latest progress of immunotherapy for small cell lung cancer

小细胞肺癌(SCLC)占所有肺癌的15%～20%,放、化疗是其主要的治疗方法,但远期控制率低。随着免疫治疗的兴起,SCLC的免疫机制被挖掘,使免疫治疗成为SCLC治疗的新突破口。CD47、DLL3、ADC作为靶点在临床前模型中显示出良好的治疗前景。免疫检查点抑制剂为SCLC的治疗提供了新的思路,但在使用上还存在争议,未达成共识。本文对SCLC免疫治疗的最新进展及其所面临的问题进行综述。

Small cell lung cancer(SCLC)accounts for15%-20%of all lung cancers.Radiotherapy and chemotherapy are the main treatment,but the long-term control rate is low.With the deepening of researches,the immune mechanism of SCLC has been excavated;immunotherapy has gradually entered the public eye,and has become a breakthrough in the treatment of SCLC.CD47,DLL3and ADC as targets show the prospect of curative effect in preclinical models.Immune checkpoint inhibitors provide new ideas for the treatment of SCLC.However,they are still controversial in their use,and no consensus has been reached.This article reviews the latest progress in immunotherapy for SCLC and the problems it faces.